Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8337856 Methods of treatment using anti-ERBB antibody-maytansinoid conjugates

Patent 8337856 was granted and assigned to Immunogen, Inc. on December, 2012 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

83378560

Patent Inventor Names

Walter Blättler0

Ravi V. J. Chari0

Date of Patent

December 25, 2012

Patent Application Number

119493510

Date Filed

December 3, 2007

Patent Citations Received

‌

US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer

‌

US Patent 11834448 2-amino-quinoline derivatives

‌

US Patent 11932650 Potent agelastatin derivatives as modulators for cancer invasion and metastasis

‌

US Patent 11965033 Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43

‌

US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer

‌

US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

‌

US Patent 11654105 Subcutaneous HER2 antibody formulations

‌

US Patent 11655305 Treatment of metastatic breast cancer

...

Patent Primary Examiner

‌

Laura B Goddard

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8337856 Methods of treatment using anti-ERBB antibody-maytansinoid conjugates

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API